title: [Explanation on indications and cost-efficiency of Inspra].
authors.affiliation: ake.ohlsson-onerud@pfizer.com
authors.forename: Ake
authors.initials: A
authors.lastname: Ohlsson-Onerud
authors.forename: Billie
authors.initials: B
authors.lastname: Pettersson
mesh_terms: D003362:Cost-Benefit Analysis; D016527:Drug Costs; D004346:Drug Information Services; D000077545:Eplerenone; D006333:Heart Failure / Q000188:drug therapy; D006801:Humans; D017410:Practice Guidelines as Topic; D013148:Spironolactone / Q000031:analogs & derivatives* / Q000191:economics* / Q000627:therapeutic use
chemical_list: D013148:Spironolactone; D000077545:Eplerenone